MINNEAPOLIS, Nov. 19, 2010 /PRNewswire/ — Uroplasty, Inc.
(Nasdaq:
UPI), a medical device company that develops, manufactures and
markets innovative proprietary products to treat voiding
dysfunctions, today announced that Palmetto GBA for California,
Nevada and Hawaii, a regional Medicare carrier, now covers
posterior tibial nerve stimulation (PTNS) using the Urgent® PC
Neuromodulation System for the treatment of the symptoms of
overactive bladder.
Palmetto GBA will cover PTNS therapy for patients who have
failed or demonstrated intolerance to standard anticholinergic drug
therapy. Coverage includes an initial course of 12 weekly PTNS
treatments, and for those patients who respond to the initial
treatments, additional treatments once every three weeks for up to
one year.
With this positive PTNS coverage and the positive coverage
announced previously by five other regional carriers, the total
number of lives covered by Medicare regional carriers is
approximately 12 million. The five other regional carriers include
Noridian Administrative Services, LLC, for North and South Dakota,
Montana, Washington, Wyoming, Utah and Arizona; Palmetto GBA for
South Carolina; CIGNA Government Services for Idaho and North
Carolina; Palmetto GBA for Ohio and West Virginia; and Pinnacle
Business Solutions for Arkansas and Louisiana.
“We believe the strong clinical data that supports PTNS led the
regional Medicare carriers to determine that PTNS treatments meet
the criteria for medical necessity,” said David Kaysen, President
and CEO of Uroplasty, Inc. “We continue to present the growing body
of clinical data to the medical directors of the other Medicare
carriers, and private payers, to encourage them to cover and
reimburse PTNS.”
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with
wholly-owned subsidiaries in The Netherlands
‘/>”/>
